Duality Biotherapeutics, Inc.
Duality Biotherapeutics, Inc., a clinical-stage biotech company, discovers and develops antibody-drug conjugate (ADC) therapeutics to treat cancer, autoimmune diseases, and others. The company provides DB-1303/BNT323, a HER2 ADC candidate targeting cancers, including endometrial cancer1 and breast cancer2; DB-1311/BNT324, a B7-H3 ADC candidate targeting cancers, such as small-cell lung cancer3, c… Read more
Duality Biotherapeutics, Inc. (4ZB) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of December 2024: -0.131x
Based on the latest financial reports, Duality Biotherapeutics, Inc. (4ZB) has a cash flow conversion efficiency ratio of -0.131x as of December 2024.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€265.36 Million) by net assets (€-2.02 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Duality Biotherapeutics, Inc. - Cash Flow Conversion Efficiency Trend (2022–2024)
This chart illustrates how Duality Biotherapeutics, Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Duality Biotherapeutics, Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Duality Biotherapeutics, Inc. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Bank First National Corp
NASDAQ:BFC
|
-0.217x |
|
Inmobiliaria Colonial SOCIMI S.A.
LSE:0RID
|
0.023x |
|
Shanghai Junshi Biosciences Co. Ltd
PINK:SHJBF
|
-0.005x |
|
Shanghai Baosight Software Co Ltd B
SHG:900926
|
0.057x |
|
Hengbao Co Ltd
SHE:002104
|
0.011x |
|
Qingdao Gaoce Technology Co Ltd
SHG:688556
|
0.024x |
|
Intercorp Financial Services Inc
NYSE:IFS
|
-0.005x |
|
Westports Holdings Berhad
PINK:WSTTF
|
0.104x |
Annual Cash Flow Conversion Efficiency for Duality Biotherapeutics, Inc. (2022–2024)
The table below shows the annual cash flow conversion efficiency of Duality Biotherapeutics, Inc. from 2022 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | €-2.02 Billion | €285.78 Million | -0.141x | +80.54% |
| 2023-12-31 | €-1.12 Billion | €816.34 Million | -0.726x | -286.54% |
| 2022-12-31 | €-769.12 Million | €-299.47 Million | 0.389x | -- |